NCT01502046 - Neuroprotection by Cannabinoids in Huntington's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

Huntington's Disease

Interventions

DRUG

delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)

Sativex 2.7 mg delta-9-tetrahydrocannabinol/2.5 mg cannabidiol Oromucosal Spray. One spray per day, up to a maximum of 12 sprays per day.

DRUG

Placebo

Placebo, One spray per day, up to a maximum of 12 sprays per day.

Trial Locations (1)

Hospital Universitario Ramón y Cajal, Madrid